Oxycodone controlled release - Pain Therapeutics

Drug Profile

Oxycodone controlled release - Pain Therapeutics

Alternative Names: ORADUR®-oxycodone; Oxycodone extended release; PF-00345439; PTI-821; Remoxy; REMOXY® ER

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator DURECT Corporation
  • Developer Pain Therapeutics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 20 Mar 2017 Pain Therapeutics announces intention to resubmit NDA to the US FDA via the 505(b) pathway for Pain (91398)
  • 20 Mar 2017 Pain Therapeutics plans a clinical abuse potential study via the intranasal route of abuse in Healthy volunteers
  • 27 Sep 2016 Pfizer receives complete response letter from the FDA for oxycodone extended-release in Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top